Promising new agents in the treatment of non-small cell lung cancer

Martin J. Edelman, David R. Gandara

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations


A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.

Original languageEnglish
Pages (from-to)385-393
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Issue number5
StatePublished - 1996


  • CPT-11
  • Docetaxel
  • Gemcitabine
  • Lung cancer
  • Topotecan
  • Vinorelbine
  • jPaclitaxel


Dive into the research topics of 'Promising new agents in the treatment of non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this